Project

RHU MARVELOUS

Goal: Myocardial infarction (120,000 cases each year in France) and ischemic stroke (130,000 cases each year in France) can be fatal or leave severe sequelae.

The MARVELOUS project will allow the development of a new, faster and more accurate method to analyse magnetic resonance imaging (MRI) images of heart or brain that are essential for optimal emergency care of these patients.

This project has been awarded 5.5 million euros, and is based on a collaboration between four academic research teams (CarMeN, CREATIS, HESPER et PhIND), Hospices Civils de Lyon and 2 private companies, Cynbiose (working with primates) and Olea Médical (developing computer tools for the analysis of radiological images). The success of this project, which will involve emergency physicians, cardiologists, neurologists, radiologists and health economists, could accelerate access to care and thus improve the prognosis for all too many patients suffering from cardiac infarction or ischemic stroke for which every minute counts.

Professor Michel Ovize who is the scientific coordinator is Professor of Cardiology at University Claude Bernard, Lyon and head of the department of cardiovascular functional explorations at Hôpital Louis Pradel, Lyon, France

This innovative and large-scale health research project will be conducted with the support of the Lyonbiopôle competitiveness cluster.

Date: 1 October 2016 - 1 September 2021

Updates
0 new
0
Recommendations
0 new
0
Followers
0 new
10
Reads
0 new
107

Project log

Claire Jossan
added a research item
Background: Several preliminary analyses suggested an association between neprilysin levels and myocardial infarction. Hypothesis: The objective was to assess whether Neprilysin (NEP) plasma levels following reperfusion might be a surrogate for infarct size (IS) or predict adverse outcomes in acute ST-segment elevation myocardial infarction (STEMI) patients. Methods: We measured NEP levels in a prospective cohort of 203 patients with STEMI referred for primary percutaneous coronary intervention. Circulating soluble NEP was measured by ELISA at admission (t0) and four hours later (t4) following reperfusion and on 7 times points (t0, t4, t12, t24, t48, day 7 and day 30) in a subset of 21 patients. Infarct size (IS) and left ejection fraction (LVEF) were measured at one month by cardiac magnetic resonance (CMR). Adverse cardiovascular outcomes were collected at 12-month follow-up. Results: Median t0 and t4 NEP levels in 203 patients were respectively 88.3 pg/mL (IQR [14; 375.4]) and 101.5 pg/mL (IQR [18.5; 423.8]). These levels remained unchanged over one month (p=0.70). NEP levels did not correlate significantly with IS (p=0.51) or LVEF (p=0.34). There was no correlation between NEP and troponin, creatine kinase and interleukin-6 levels at h0 and h4. NEP levels above the median were not associated with adverse outcomes at follow-up (HR= 1.28, 95%CI [0.69; 2.37]; p=0.42). Conclusions: NEP serum levels were widely distributed and did not change significantly in the first hours and one-month period following reperfusion in STEMI patients. There was no significant relationship with markers of infarct size and inflammation, and one-year adverse outcomes.
Camille Amaz
added a project goal
Myocardial infarction (120,000 cases each year in France) and ischemic stroke (130,000 cases each year in France) can be fatal or leave severe sequelae.
The MARVELOUS project will allow the development of a new, faster and more accurate method to analyse magnetic resonance imaging (MRI) images of heart or brain that are essential for optimal emergency care of these patients.
This project has been awarded 5.5 million euros, and is based on a collaboration between four academic research teams (CarMeN, CREATIS, HESPER et PhIND), Hospices Civils de Lyon and 2 private companies, Cynbiose (working with primates) and Olea Médical (developing computer tools for the analysis of radiological images). The success of this project, which will involve emergency physicians, cardiologists, neurologists, radiologists and health economists, could accelerate access to care and thus improve the prognosis for all too many patients suffering from cardiac infarction or ischemic stroke for which every minute counts.
Professor Michel Ovize who is the scientific coordinator is Professor of Cardiology at University Claude Bernard, Lyon and head of the department of cardiovascular functional explorations at Hôpital Louis Pradel, Lyon, France
This innovative and large-scale health research project will be conducted with the support of the Lyonbiopôle competitiveness cluster.